Alnylam Pharmaceuticals, a biotech company, faced a common challenge: securing significant funding for its promising cholesterol drug, inclisiran. While traditional funding routes often fall short for intellectual property (IP)-rich companies, Alnylam found a powerful solution in 2019. They secured a $1 billion funding package from Blackstone Life Sciences by monetizing future royalties from inclisiran. This was possible because Blackstone, a specialized IP investor, recognized the predictable, long-term royalty streams generated by Alnylam’s licensing agreements. This success story demonstrates how the right funders—be they banks, private equity, or royalty finance firms—are eager to step in when IP proves its commercial traction.
The Expanding Landscape of IP Funders
Not long ago, only a handful of specialized firms considered IP-backed deals. Today, the ecosystem is much broader. From global banks to boutique funds, a growing number of players are providing capital secured by intellectual property. Each type of funder has its own risk appetite, preferred industries, and deal structures.
Banks and Asset-Based Lenders
Some commercial banks now recognize licensing royalties as legitimate collateral, particularly when backed by strong partners or established markets. These deals often resemble asset-backed lending, where the royalty stream is pledged against a loan. Banks prefer late-stage IP with proven, recurring revenues and transparent agreements.
Example: Silicon Valley Bank, before its collapse in 2023, frequently provided credit facilities backed by IP portfolios in tech and life sciences.
Private Equity and Venture Investors
Private equity and venture capital firms are increasingly attracted to IP-driven businesses. While they often invest in the company itself, licensing revenues strengthen valuations and justify larger equity rounds. Hybrid licensing-plus-equity deals are especially common, where investors receive both an ownership stake and a share of licensing revenues.
Example: KKR has invested heavily in healthcare and biotech companies with strong licensing pipelines, structuring deals around both equity and future royalties.
Royalty Finance Specialists
Specialized firms such as Royalty Pharma, HealthCare Royalty Partners, and DRI Capital focus entirely on acquiring or financing royalty streams. These players provide upfront cash in exchange for a portion of future licensing revenues. Their model is built on detailed due diligence and valuation of IP-backed cash flows. For IP owners, this can be one of the fastest ways to unlock large-scale funding without diluting ownership.
Government and Development Agencies
In some sectors, particularly energy, clean tech, and life sciences, government agencies and development funds also step in. These entities may not be traditional investors, but they provide grants, loans, or guarantees that lower the risk of commercialization. Licensing agreements often strengthen these applications by demonstrating real-world adoption.
Corporate Partners
In many industries, large corporations act as funders through strategic licensing deals. These companies provide upfront milestone payments, co-development funding, or market entry support in exchange for rights to IP. While technically licensing partners, they are also acting as financiers, bridging the gap between development and commercialization.
Example: In medtech and biotech, milestone-driven licensing deals often include hundreds of millions in upfront and staged payments—effectively providing financing while validating the IP’s market readiness.
The Bigger Picture
IP funding is no longer a niche activity. From global banks to boutique royalty funds, the ecosystem of capital providers has expanded dramatically. The common denominator: all of them require market-ready IP and commercially structured licensing deals. The better your licensing strategy demonstrates predictable royalties and partner traction, the wider your funding options become.
How We Help You Connect with IP Funders
At Licensing Consulting Group, we focus on commercializing market-ready IP through licensing so that funders view your portfolio as a financeable asset. We don’t just talk about protection—we help you build traction that attracts the attention of banks, private equity firms, and royalty finance specialists.
Our services are designed to help you:
- Develop licensing campaigns that validate your IP and generate royalty streams.
- Identify and secure partners that make your IP attractive to funders.
- Position your IP portfolio for introductions to banks, private equity, and royalty funds.
- Create commercialization strategies that highlight growth potential funders want to see.
Next step: Book a 15-Minute Call to discuss how we can help you commercialize your IP through licensing and connect with the right funders.
Stay connected: Sign up for our newsletter for strategies, case studies, and insights on using licensing to generate revenue and position your IP for potential funding opportunities.
Rand Brenner is an IP professional whose passion is helping inventors, startups, and businesses use licensing to turn their IP into income-producing products, services, and technologies. His decades of experience run the gamut from medical devices to food technology to consumer products. He’s licensed some of the biggest Hollywood entertainment blockbusters, including the Batman Movies (1 and 2) and the number one kid’s action TV show, the Mighty Morphin Power Rangers. Rand speaks about licensing and is a featured speaker at investment conferences, trade shows, colleges, and startup events. His first book, Hidden Wealth: The Money-Making Power of Licensing, was released in 2019 and is available on Amazon.com. He’s also a published writer, and his articles have appeared in several prestigious trade magazines, including The Licensing Journal, Intellectual Property Magazine, and License India.
Working Through a Licensing or Commercialization Challenge?
If you have market-ready intellectual property, a licensing campaign that has stalled, or a business opportunity that may benefit from licensing, a short strategy discussion can help clarify the next step.